lmb-9
mAbexperimentalADC
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 1998 (NCT00019435)
Timeline
1990s
- Jan 1, 1998
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lewis Y antigenBINDING AGENT
Lewis Y antigen binding agent
- Elongation factor 2INHIBITOR
Elongation factor 2 inhibitor
- Lewis Y antigenImmunity, passive
Lewis Y antigen immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin A
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109503 ↗
Also known as
- b3 (dsfv) -pe (pseudomonas aeruginosa exotoxin a)38
- lmb-9
- lmb-9
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00010270 | Phase 1 | Apr 1, 2001 | National Cancer Institute (NCI), University of Freiburg |
| NCT00005858 | Phase 1 | Apr 1, 2000 | Johns Hopkins University, National Cancer Institute (NCI), University of Maryland |
| NCT00019435 | Phase 1 | May 1, 1998 | National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 1 | 1 | 1998 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2000 |
| University of Freiburg | Academic/Hospital | 1 | 1 | 1 | 2001 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2000 |
4 organizations
Page 1 / 1